Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Remarkable data: trastuzumab deruxtecan for HER2+ BC

Sandra Swain • 13 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Pertuzumab Trastuzumab Trastuzumab deruxtecan

Sandra Swain, MD, FACP, Georgetown University Medical Center, Washington, DC, discusses the use of trastuzimab deruxtecan for the treatment of HER2+ breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sandra Swain

2:43
CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art
Sandra Swain • 7 May 2020
1:56
NSABP B-41: genes and signatures associated with pCR
Sandra Swain • 7 May 2020
2:40
CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC
Sandra Swain • 8 May 2020
1:37
Breast cancer: SAFE-HEaRt study
Sandra Swain • 3 Jun 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals